Adagene Inc.
ADAG
$3.35
-$0.14-4.01%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index
Headlines
5/19/2026
-
MarketBeat
9/9/2026
-
TipRanks
9/9/2026
-
Globe Newswire
9/9/2026
-
Tickeron - Stocks
9/9/2026
-
Tickeron - Stocks
9/5/2026
-
Tickeron - Stocks
9/4/2026
-
Tickeron - Stocks
9/1/2026
-
Tickeron - Stocks
8/29/2026
-
Tickeron - Stocks
8/29/2026
-
Tickeron - Stocks
8/29/2026
-
Tickeron - Stocks
8/27/2026
-
Tickeron - Stocks
8/26/2026
-
Tickeron - Stocks
8/26/2026
-
Tickeron - Stocks
8/26/2026
-
MarketBeat
8/20/2026
-
Globe Newswire
8/20/2026
-
Tickeron - Stocks
8/19/2026
-
Tickeron - Stocks
8/17/2026
-
TipRanks
8/15/2026
-
Tickeron - Stocks
8/15/2026
-
Tickeron - Stocks
8/14/2026
-
Tickeron - Stocks
8/13/2026
-
Tickeron - Stocks
8/12/2026
-
TipRanks
8/9/2026
-
The Cerbat Gem
Income Statement
Total Revenue (TTM)
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Wednesday, August 12, 2026
Period Date
Tuesday, June 30, 2026
Next Filing
Beginning of April (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
86 512 8777 3632
Address
Building C14
4th Floor
No. 218, Xinghu Street
Suzhou Industrial Park
Suzhou, 215123
4th Floor
No. 218, Xinghu Street
Suzhou Industrial Park
Suzhou, 215123
Country
Year Founded
Business Description
Sector
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People’s Republic of China. Its lead...
more